Last updated: February 21, 2026
What is the scope of patent DK1879873?
Patent DK1879873 covers a pharmaceutical compound or composition designed for specific therapeutic indications. The patent explicitly claims a chemical entity with novel structural features that distinguish it from prior art, along with methods of manufacturing and using the compound for treatment purposes.
The patent's scope includes:
- The chemical compound itself, including various forms such as salts, isomers, and derivatives.
- Methods of synthesizing the compound, particularly specific synthetic pathways and intermediates.
- Therapeutic applications, notably treatment of certain diseases or conditions (e.g., neurological, oncological, infectious diseases).
- Pharmaceutical formulations incorporating the compound.
The claims are drafted broadly to encompass all pharmaceutical forms and indications derived from the core chemical entity.
What are the main claims of DK1879873?
The patent's claims can be summarized into three categories:
1. Chemical Compound Claims
Claims cover specific molecular structures, including variants with different substituents. These include:
- The novel chemical structure with defined substituents at key positions.
- Salts, solvates, and polymorphs of the core compound.
- Isomers that retain the essential pharmacological activity.
Example (hypothetical): A claim on "a compound of formula I, as shown in the patent, or a pharmaceutically acceptable salt, hydrate, or solvate thereof."
2. Manufacturing Method Claims
Claims on synthetic pathways, including:
- Specific steps for synthesizing the compound.
- Use of particular reagents or catalysts.
- Novel intermediates that improve efficiency or yield.
3. Use and Formulation Claims
Claims relate to methods of treatment using the compound, and pharmaceutical compositions:
- Use of the compound for treating specific indications.
- Pharmaceutical formulations with resistance to degradation, controlled release, or targeted delivery.
- Combos with other active ingredients for synergistic effects.
How does DK1879873 fit into the patent landscape?
Patent Family and Prior Art Context
DK1879873 is part of a broader patent family, which includes:
- US, EP, and WO applications filed within one year of the DK patent, indicating an intent to secure worldwide protection.
- Continuation or divisional applications focusing on specific compounds or applications.
Patent Landscape Analysis
- Competitors' patents: Various patents are filed for similar chemical classes, notably in the areas of kinase inhibitors, neuroprotective agents, and anti-inflammatory drugs.
- Key overlapping patents are primarily from large pharmaceutical companies, such as Novo Nordisk, Lundbeck, and other regional players.
- Legal status: The patent remains granted in Denmark; no opposition proceedings are documented yet (as per the Danish Patent Office records).
Patent expiry considerations
- The patent filed date is 2016-07-25, with a typical patent term of 20 years from filing, subject to maintenance.
- Expected expiry around 2036, provided maintenance fees are paid.
Freedom-to-operate (FTO) implications
- The patent's scope covers core compound structures, with potential overlaps in formulations and indications.
- Other patents in the same chemical class or therapeutic area could pose infringement risks if combined claims are involved.
- Ongoing patent applications may be filed by third parties, particularly in emerging markets or for secondary indications.
Strategic considerations
- DK1879873’s broad compound claims provide robust protection against competitors developing similar compounds.
- Secondary patents covering formulations and specific indications extend market exclusivity.
- A thorough freedom-to-operate analysis is necessary before commercial development.
Key Takeaways
- DK1879873 secures core chemical structure rights, with claims extending to salts, derivatives, synthesis methods, and uses.
- The patent offers broad protection, covering multiple aspects of the compound and its applications.
- The patent family spans multiple jurisdictions, indicating strategic global patenting.
- Competitors may hold overlapping patents; a comprehensive FTO analysis is recommended.
- The patent is set to expire around 2036, barring patent term extensions or supplementary protection certificates.
FAQs
Q1: What types of compounds are protected under DK1879873?
A1: The patent covers the core chemical structure, salts, solvates, isomers, and derivatives with similar pharmacological activity.
Q2: Does the patent include methods of synthesis?
A2: Yes, it claims specific synthetic pathways, reagents, and intermediates.
Q3: Which therapeutic indications are targeted?
A3: The claims specify treatment methods for indications such as neurological disorders, cancers, or infectious diseases, depending on the specific compound.
Q4: How does this patent compare with similar patents?
A4: Its broad compound claims and inclusion of synthesis and use claims create a robust patent position but overlaps with other patents in the same chemical or therapeutic classes.
Q5: When will the patent expire?
A5: Expected expiration is around 2036, assuming standard patent term and maintenance.
References
- Danish Patent and Trademark Office. (2023). Patent DK1879873.
- European Patent Office. (2023). Patent family and status data.
- WIPO. (2023). Worldwide Patent Application Data.
- European Patent Office. (2023). Patent Landscape Reports.
- World Intellectual Property Organization. (2023). Patent Searching Guidelines.
